High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

导出原文传递

翻译打印收藏纠错

作者： Gane, Edward ^[1] ; Poordad, Fred ^[2] ; Wang, Stanley ^[3] ; Asatryan, Armen ^[4] ; Kwo, Paul Y. ^[5] ; Lalezari, Jacob ^[6] ; Wyles, David L. ^[7] ; Hassanein, Tarek ^[8] ; Aguilar, Humberto ^[9] ; Maliakkal, Benedict ; Liu, Ran ; Lin, Chih-Wei ; Ng, Teresa I. ; Kort, Jens ; Mensa, Federico J.

作者单位： Univ Auckland, 2 Pk Rd, Auckland 1023, New Zealand ^[1] Quest Clin Res, San Francisco, CA USA ^[2] Louisiana Res Ctr, Shreveport, LA USA ^[3] AbbVie Inc, N Chicago, IL USA ^[4] Univ Calif San Diego, La Jolla, CA 92093 USA ^[5] Southern Calif GI Ctr, Coronado, CA USA ^[6] Indiana Univ Sch Med, Indianapolis, IN 46202 USA ^[7] Univ Rochester, Med Ctr, Rochester, NY 14642 USA ^[8] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA ^[9]

关键词 Hepatitis C Pibrentasvir Glecaprevir SURVEYOR

发布时间 2017-04-24

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Gastroenterology

2016年151卷4期

651-659页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

Gastroenterology

相似文献

Gastroenterology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis

Gastroenterology

相似文献

Gastroenterology

相关期刊

检索历史清除